Research programme: eye disorder therapeutics - GrayBug

Drug Profile

Research programme: eye disorder therapeutics - GrayBug

Alternative Names: GB-201- GrayBug Vision; GB-202; GB-203

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GrayBug inc.
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma; Wet age-related macular degeneration

Most Recent Events

  • 10 May 2017 Early research in Glaucoma in USA (Subconjunctival) (Graybug pipeline, May 2017)
  • 10 May 2017 Preclinical trials in Keratoplasty rejection (Corneal graft rejection) in USA (unspecified route) (Graybug pipeline, May 2017)
  • 10 May 2017 Preclinical trials in Wet age-related macular degeneration in USA (Intravitreous) (Graybug pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top